<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Acumen Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc</link>
<description>Latest news and press releases for Acumen Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 12 May 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/acumen-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835416178dffbe2df0e0d5a.webp</url>
<title>Acumen Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc</link>
</image>
<item>
<title>Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-highlights</guid>
<pubDate>Tue, 12 May 2026 11:00:00 GMT</pubDate>
<description>Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Lead clinical candidate IND filing in Acumen’s EBDTM (enhanced brain delivery) program targeted for mid-2027Cash, cash equivalents and marketable securities of $128.4 million as of Mar. 31, 2026, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m.</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-participate-in-the-bank-of-america-securities-2026-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-participate-in-the-bank-of-america-securities-2026-health-care-conference</guid>
<pubDate>Thu, 07 May 2026 20:00:00 GMT</pubDate>
<description>NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 8:55 a.m. PT/11:55 a.m. ET. The live webcast may be accessed under the Investors ta</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-12-2026</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-12-2026</guid>
<pubDate>Tue, 05 May 2026 20:00:00 GMT</pubDate>
<description>NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter financial results on Tuesday, May 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financi</description>
</item>
<item>
<title>Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-reports-financial-results-for-the-year-ended-december-31-2025-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-reports-financial-results-for-the-year-ended-december-31-2025-and-business-highlights</guid>
<pubDate>Thu, 26 Mar 2026 11:00:00 GMT</pubDate>
<description>Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Lead clinical candidate IND filing in Acumen’s Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolioCash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to suppor</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2025-financial-results-on-march-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2025-financial-results-on-march-26-2026</guid>
<pubDate>Thu, 19 Mar 2026 20:00:00 GMT</pubDate>
<description>NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provid</description>
</item>
<item>
<title>Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-deliverytm-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimers-and-parkinsons-diseases-2026</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-presents-studies-on-enhanced-brain-deliverytm-biomarker-research-and-novel-antibodies-at-advances-in-alzheimers-treatment-at-international-conference-on-alzheimers-and-parkinsons-diseases-2026</guid>
<pubDate>Tue, 17 Mar 2026 12:00:00 GMT</pubDate>
<description>NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD), taking place March 17-21, in Copenhagen and online. Shared in one oral and two po</description>
</item>
<item>
<title>Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-announces-dollar3575-million-private-placement-to-advance-potential-best-in-class-molecules-from-amyloid-beta-oligomer-selective-enhanced-brain-delivery-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-announces-dollar3575-million-private-placement-to-advance-potential-best-in-class-molecules-from-amyloid-beta-oligomer-selective-enhanced-brain-delivery-portfolio</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-participate-in-the-stifel-2026-virtual-cns-forum-14</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-participate-in-the-stifel-2026-virtual-cns-forum-14</guid>
<pubDate>Tue, 10 Mar 2026 20:00:00 GMT</pubDate>
<description>NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-showcase-advances-in-alzheimers-treatment-at-international-conference-on-alzheimers-and-parkinsons-diseases-2026</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-to-showcase-advances-in-alzheimers-treatment-at-international-conference-on-alzheimers-and-parkinsons-diseases-2026</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), announced today one oral and two poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) taking place in Copenhagen. The presentations will highlight new</description>
</item>
<item>
<title>Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-highlights-enhanced-brain-130000021</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-highlights-enhanced-brain-130000021</guid>
<pubDate>Tue, 02 Dec 2025 13:00:00 GMT</pubDate>
<description>NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced new research at the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place December 1-4, 2025, in San Diego and online. Results from a collaborative study with JCR Pharmaceuticals demonstrat</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-present-recruitment-strategies-130000582</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-present-recruitment-strategies-130000582</guid>
<pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
<description>NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it will present new findings at the upcoming 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in San Diego. The presentations include Acumen’s recruitment strategies for its Phase</description>
</item>
<item>
<title>Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-announces-first-participant-130000840</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-announces-first-participant-130000840</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>NEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in people with early Alzheimer's disease. The open-label exte</description>
</item>
<item>
<title>Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-reports-third-quarter-120000888</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-reports-third-quarter-120000888</guid>
<pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
<description>Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Cash, cash equivalents and marketable securities of $136.1 million as of Sept. 30, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast</description>
</item>
<item>
<title>Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-appoints-george-golumbeski-130000603</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-appoints-george-golumbeski-130000603</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive experti</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-report-third-quarter-210000278</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-report-third-quarter-210000278</guid>
<pubDate>Wed, 05 Nov 2025 21:00:00 GMT</pubDate>
<description>NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter 2025 financial results on Wednesday, November 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a busin</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-participate-stifel-healthcare-210000845</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-participate-stifel-healthcare-210000845</guid>
<pubDate>Tue, 04 Nov 2025 21:00:00 GMT</pubDate>
<description>NEWTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025, at 4:40 p.m. ET. The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be a</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-participate-upcoming-investor-200000568</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-participate-upcoming-investor-200000568</guid>
<pubDate>Tue, 26 Aug 2025 20:00:00 GMT</pubDate>
<description>NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences. Citi’s 2025 Biopharma Back to School Conference Date/Time: Fireside chat on Tuesday, September 2, 2025 at 3:15 p.m. ET Cantor Global Healthcare C</description>
</item>
<item>
<title>Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-reports-second-quarter-110000834</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-reports-second-quarter-110000834</guid>
<pubDate>Tue, 12 Aug 2025 11:00:00 GMT</pubDate>
<description>Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Expect decision to advance an oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Cash, cash equivalents and marketable securities of $166.2 million as of June 30, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET</description>
</item>
<item>
<title>Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-report-second-quarter-200000599</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-report-second-quarter-200000599</guid>
<pubDate>Tue, 05 Aug 2025 20:00:00 GMT</pubDate>
<description>NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter 2025 financial results on Tuesday, August 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business</description>
</item>
<item>
<title>Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025</title>
<link>https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-presents-studies-showing-120000805</link>
<guid isPermaLink="true">https://6ix.com/company/acumen-pharmaceuticals-inc/news/acumen-pharmaceuticals-presents-studies-showing-120000805</guid>
<pubDate>Mon, 28 Jul 2025 12:00:00 GMT</pubDate>
<description>NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced results showing that implementing a blood-based pTau217 screening assay reduced Acumen’s overall clinical trial screening costs by approximately 40% in its Phase 2 ALTITUDE-AD study of sabirnetug in early Alzheimer’s d</description>
</item>
</channel>
</rss>